SCHEMBL5010664

SCHEMBL5010664

CCCCN(C(=O)c1cc(NC(=O)c2cc(F)c(F)cc2Cl)[nH]n1)c1ccc(CC(=O)OCC)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.41
RECQL P46063 1/20 0.41
CYP2C19 P33261 3/20 0.36
CYP1A2 P05177 2/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MAPT P10636 3/20 0.34
CETP P11597 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
CYP4Z1 Q86W10 1/20 0.33
PYGL P06737 1/20 0.33
CYP3A4 P08684 3/20 0.33
HSP90AA1 P07900 1/20 0.33
PPARG P37231 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5008214 0.90 HTT (0.41) HTTRECQLCYP2C19CYP1A2NPC1
SCHEMBL5012188 0.89 HTT (0.42) HTTRECQLCYP2C19CYP1A2NPC1
SCHEMBL14587755 0.86 SMN1; SMN2 (0.40) HTTRECQLCYP2C19CYP1A2NPC1
SCHEMBL5013610 0.86 HTT (0.45) HTTRECQLCYP2C19CYP1A2NPC1
SCHEMBL5010820 0.85 HTT (0.43) HTTRECQLCYP2C19CYP1A2NPC1
SCHEMBL5013398 0.83 HTT (0.44) HTTRECQLCYP2C19CYP1A2NPC1
SCHEMBL14587749 0.82 PRSS12 (0.41) HTTRECQLCYP2C19NPC1RAB9A
SCHEMBL5010563 0.80 HTT (0.41) HTTRECQLCYP2C19NPC1RAB9A
SCHEMBL5010390 0.79 HTT (0.47) HTTRECQLCYP2C19CYP1A2NPC1
SCHEMBL14587752 0.78 HTT (0.41) HTTRECQLCYP2C19NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL HTT 4237/4885RECQL 766/4885CYP2C19 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.